Bagel, J., A. . Armstrong, R. Warren, K. Papp, D. Thaçi, A. Menter, J. Cather, M. Augustin, L. Hippeli, C. Daamen, and C. Griffiths. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s47, doi:10.25251/skin.6.supp.47.